JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meffin, P. J.
Right arrow Articles by Veenendaal, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meffin, P. J.
Right arrow Articles by Veenendaal, J. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CLOFIBRATE
*PROBENECID

A renal mechanism for the clofibric acid-probenecid interaction

PJ Meffin, DM Zilm and JR Veenendaal

A rabbit model has been used to investigate two hypotheses for the decrease in clofibric acid plasma clearance on probenecid coadministration in man. Rabbits administered probenecid (10 mg/kg followed by 10 mg/kg/hr) showed a mean reduction from control values of 68% for clofibric acid plasma clearance, 80% for clofibric acid glucuronide renal clearance and an elevation in the area under the plasma clofibric acid glucuronide concentration-time curve of 5.2-fold. These findings support the hypotheses that the decrease in clofibric acid plasma clearance involves the inhibition of the renal secretion of clofibric acid glucuronide by probenecid and the subsequent hydrolysis of the glucuronide as the major mechanism, rather than direct inhibition of clofibric acid glucuronide synthesis by probenecid, but do not exclude a mechanism in which both processes operate.

Volume 227, Issue 3, pp. 739-742, 12/01/1983
Copyright © 1983 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
L. Sabordo, B. C. Sallustio, A. M. Evans, and R. L. Nation
Hepatic Disposition of the Acyl Glucuronide1-O-Gemfibrozil-beta -D-Glucuronide: Effects of Dibromosulfophthalein on Membrane Transport and Aglycone Formation
J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 414 - 420.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1983 by the American Society for Pharmacology and Experimental Therapeutics.